SCYNEXIS, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-12-31 was $0.00.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-09-30 was $0.00.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-06-30 was $2.98M.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $7.45M, a 42.72% increase from fiscal 2020.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $5.22M, a 75.00% increase from fiscal 2019.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $2.98M.
- SCYNEXIS, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2014 was $88.79M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2021-12-31 | $7.45M 10-K · filed 2023-03-31 | |
| 2020-12-31 | $5.22M 10-K · filed 2022-03-29 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.98M 10-K · filed 2021-03-29 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2019-06-30 | $2.98M 10-Q · filed 2019-08-07 | |
| 2014-12-31 | $88.79M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |